DRD2 and schizophrenia: The Dopamine D2 receptor (DRD2) is a target for antipsychotic drugs in the treatment of schizophrenia [20] and genetic variation within and adjacent to DRD2 has been associated with schizophrenia [21,22], including in a recent large genome-wide association study [23].